CD83 Biomarker Measurement for GvHD Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Graft versus Host Disease (GvHD) often involve broad immunosuppressive therapies, which can be unnecessary and prolonged, highlighting the need for improved methods to identify and treat subjects at risk of allo- or autoimmune conditions before symptom onset.
Innovation Solution
The method involves measuring CD83 expression in specific populations of immune cells, such as CD4+ T cells for acute GvHD and CD19+ B cells or T helper follicular cells for chronic GvHD, to identify at-risk subjects, followed by administration of a CD83-targeted therapeutic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad immunosuppressive therapies are administered to prevent GvHD, then the risk of GvHD is reduced, but unnecessary and prolonged treatment is imposed on patients
Solution Approach 1:
The patent applies preliminary action by measuring CD83 expression on donor T cells before transplantation to identify patients at high risk of GvHD. This allows for risk stratification and personalized prophylaxis decisions, enabling early intervention only for those who need it most, thereby avoiding unnecessary prolonged treatment for low-risk patients while maintaining reliable GvHD prevention for high-risk individuals.
2Reliability
If broad immunosuppressive therapies are administered to prevent GvHD, then the risk of GvHD is reduced, but unnecessary treatment is imposed on patients
Solution Approach 1:
The patent applies local quality by transitioning from uniform broad immunosuppression to personalized treatment based on individual risk profiles. By measuring CD83 expression on donor T cells, the system identifies specific patients with high risk of GvHD and targets immunosuppressive therapy only to those individuals, making the treatment necessary and appropriate only for those who need it, rather than imposing it on all patients uniformly.
3Ease of operation
If CD83-targeted therapeutics are administered, then treatment specificity is improved, but identification and measurement complexity increases
Solution Approach 1:
The patent applies the color changes principle by using flow cytometry to detect CD83 expression on donor T cells through fluorescent labeling. The measurement system utilizes fluorescent dyes that bind to CD83, causing a detectable color/fluorescence change that indicates the presence and level of CD83 expression. This allows for standardized, automated measurement of CD83 levels on cell surfaces, simplifying the identification process while maintaining high treatment specificity through CD83-targeted therapeutics.
Data Source
AI summary
The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.